APDM PHARMS
GenericsAPDM PHARMS is a generic drug manufacturer focused on Cardiovascular.
APDM PHARMS's Key Drugs
APDM PHARMS's core commercial portfolio centers on AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
APDM PHARMS's Recent FDA Approvals
New NDA/BLA approvals for APDM PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
APDM PHARMS's Therapeutic Areas
APDM PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
APDM PHARMS's Top Competitors
APDM PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
APDM PHARMS Pipeline Snapshot
Active clinical trials for APDM PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-01-11
- Latest
- 2023-09-18
- Applications
- 1